Goldman Sachs Group Inc Biomarin Pharmaceutical Inc Call Options Transaction History

Goldman Sachs Group Inc

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 13, 2024	BUY	$76.22 - $98.51 $4.21 Million - $5.45 Million	55,300 New	55,300 $5.33 Million
Q3 2022 May 14, 2024	SELL	$82.16 - $96.94 $2.09 Million - $2.46 Million	-25,400 Reduced 45.93%	29,900 $2.54 Million
Q3 2022 Nov 10, 2022	BUY	$82.16 - $96.94 $2.46 Million - $2.9 Million	29,900 New	29,900 $2.53 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.